This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Atrial fibrillation (AF) affects over 37 million people globally and is the leading cause of cardioembolic stroke. The treatment landscape is evolving rapidly in 2026: pulsed field ablation (PFA) has emerged as a safer, faster catheter ablation technique that is replacing radiofrequency ablation in many centers; the CHAMPION-AF trial is testing whether ablation is superior to drug therapy as first-line treatment; next-generation anticoagulants targeting factor XIa promise anticoagulation with dramatically reduced bleeding risk; and LAA closure devices are being compared directly to anticoagulation in broad populations.
Pulsed Field Ablation: A Safer Way to Isolate the Pulmonary Veins
Catheter ablation for AF works by electrically isolating the pulmonary veins — where most AF triggers originate — from the left atrium. Traditional radiofrequency (RF) ablation uses heat to create scar tissue, while cryoablation uses extreme cold. Both can inadvertently injure adjacent structures including the esophagus, phrenic nerve, and pulmonary veins themselves, leading to rare but serious complications.
Pulsed field ablation (PFA) delivers ultra-short, high-voltage electrical pulses that cause irreversible electroporation — disruption of cell membranes causing cell death — in cardiac tissue while sparing non-cardiac tissues (esophagus, nerves) due to their different electrical properties. This tissue selectivity is its key advantage. The ADVENT trial (Medtronic FARAPULSE system) published in NEJM showed PFA was non-inferior to thermal ablation for AF recurrence but with significantly fewer complications — 0% esophageal injury vs. rare but present with RF.
PFA received FDA approval in 2023 and has been adopted with extraordinary speed. Multiple PFA platforms are now in trials (Medtronic FARAPULSE, Boston Scientific FARAWAVE, Biosense Webster varipulse), and comparative trials of PFA vs. cryoablation and RF in paroxysmal, persistent, and long-standing persistent AF are underway in 2026.
CHAMPION-AF: Ablation vs. Drugs as First-Line Therapy
Current guidelines recommend anti-arrhythmic drugs (AADs) as first-line rhythm control for most AF patients, with catheter ablation reserved for those who fail or are intolerant of AADs. The CHAMPION-AF trial is directly challenging this paradigm: it is a large randomized trial comparing catheter ablation (RF or cryoablation) to AAD therapy as the initial rhythm-control strategy in patients with newly diagnosed AF.
Observational data and earlier trials (EARLY-AF, STOP-AF, CATHARSIS) have consistently suggested ablation achieves more durable sinus rhythm maintenance than AADs and may have favorable effects on quality of life, hospitalization, and possibly long-term cardiovascular outcomes. If CHAMPION-AF confirms a meaningful superiority, it would be expected to shift guidelines to recommend ablation — particularly PFA — as first-line therapy for symptomatic AF, dramatically increasing procedural volume.
Factor XIa Inhibitors: Anticoagulation Without the Bleeding
The most significant limitation of anticoagulation for AF stroke prevention is bleeding risk — both major bleeding (intracranial hemorrhage, GI bleeding) and the cumulative burden of minor bleeds. Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban have reduced bleeding compared to warfarin, but clinically significant bleeding remains a major cause of treatment discontinuation.
Factor XIa is part of the intrinsic coagulation pathway involved in thrombosis amplification but plays a lesser role in hemostasis (the normal clot-forming response to injury). Inhibiting factor XIa may therefore prevent pathological thrombosis (clots in the heart causing stroke) without significantly impairing the body's ability to stop bleeding from wounds.
Asundexian (BAY 2433334, Bayer) and milvexian (BMS/Janssen) are oral factor XIa inhibitors in Phase 3 AF trials. The OCEANIC-AF trial compared asundexian to apixaban in AF stroke prevention. Preliminary results showed asundexian had lower bleeding (as expected) but numerically more strokes — suggesting the dose or mechanism may require refinement. Milvexian and abelacimab (anti-FXI antibody) are in ongoing Phase 3 trials with different dosing strategies.
Left Atrial Appendage Closure vs. Anticoagulation
In AF, approximately 90% of cardioembolic clots originate in the left atrial appendage (LAA) — a finger-like pouch in the left atrium where blood stagnates during AF. Mechanical occlusion of the LAA with an implantable device (Watchman FLX, Amulet) eliminates this clot source without requiring lifelong anticoagulation — potentially ideal for patients at high bleeding risk.
The PROTECT-AF and PREVAIL trials established LAA closure as non-inferior to warfarin. Current trials are comparing Watchman FLX directly to DOACs (the CHAMPION-AF-Watchman trial and CATALYST trial), which represent the current standard of care rather than warfarin. The LAAOS III trial, which added LAA surgical closure during cardiac surgery to standard care, showed a 33% reduction in stroke — the first randomized evidence that LAA closure prevents stroke, lending mechanistic support to the percutaneous approach.
Key Takeaways
- Pulsed field ablation (PFA) is FDA-approved and being adopted rapidly for AF ablation — it spares non-cardiac tissues and reduces esophageal injury risk dramatically.
- CHAMPION-AF is testing ablation vs. AADs as first-line therapy; if positive, it could fundamentally shift AF rhythm-control guidelines.
- Factor XIa inhibitors (asundexian, milvexian) aim to prevent AF-related stroke with less bleeding than DOACs, but Phase 3 efficacy data are still evolving.
- LAA closure (Watchman FLX) is being directly compared to DOACs in several Phase 3 trials, potentially expanding its use to AF patients able to take anticoagulants.
- LAAOS III demonstrated a 33% stroke reduction with surgical LAA closure — providing the clearest mechanistic validation of LAA-targeted stroke prevention to date.